Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma

Mahdi, Haider; Xiu, Joanne; Reddy, Sandeep K.; Debernardo, Robert

doi:10.1002/jso.23993

Cited by 15 publications

(7 citation statements)

References 29 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other frequent mutations but poorly understood are RB1 (retinoblastoma) deletions in high-grade serous carcinoma 19 . Compared to other localizations, alteration in PI3K/mTOR, MAPK pathways and HER2 expression/amplification is more frequent in uterine serous carcinoma than in ovarian serous carcinoma 20 .…”

Section: Resultsmentioning

confidence: 72%

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

Popa¹,

COROBEA²,

Munteanu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Comparaison entre les deux types de carcinome séreux de l'ovaire, à haut et à bas degré-diagnostic différentiel courant et perspectives Introduction. Le carcinome séreux est responsable de 47% de tous les cancers de l'ovaire. Parmi ces cas, 5% seulement sont représentés par un carcinome séreux à bas degré, le reste d'entre eux représentant un carcinome séreux à haut degré. Objectifs. Le but de cette étude est une approche observationnelle des différences et des similitudes entre les deux types de carcinome séreux de l'ovaire, qui doivent être considérés comme des formes différentes de cancer et traités avec précaution. Méthodes. Nous avons réalisé une étude rétrospective utilisant trois cas de carcinome séreux ovarien à haut degré et trois cas de carcinome séreux à bas degré ovarien, diagnostiqués à l'Hôpital Universitaire d'Urgence de Bucarest. Nous avons analysé l'âge des patients, les symptômes cliniques, les caractéristiques ABSTRACT Introduction. Serous carcinoma is responsible for 47% of all ovarian cancers, and from these cases, only 5% are represented by low-grade serous carcinoma, the rest of them accounting for high-grade serous carcinoma. Objective. The aim of this study is an observational approach of the differences and similarities of the two types of serous carcinoma of the ovary, that must be seen as different forms of cancer and rendered with care. Methods. We performed a retrospective study using three cases of ovarian high-grade serous carcinoma and three cases of ovarian low-grade serous carcinoma, diagnosed at the University Emergency Hospital Bucharest. We analyzed patients' age, clinical symptoms, macroscopic and microscopic features together with immunohistochemistry tests. Results. Mean age for HG carcinoma was 71.3 years old and for LG carcinoma 47.6 years old. Average tumor diameter was with 5.67 cm higher for LG carcinoma. The most encountered stage for HG tumors was pT2a and for LG tumors was pT1a. Mean value

show abstract

Section: Resultsmentioning

confidence: 72%

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

Popa¹,

COROBEA²,

Munteanu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

show abstract

“…Details about the literature search results are reported in Figure 1 . A total of 11/25 included studies that assessed the prevalence of BRCAm in patients affected by endometrial cancer [ 8 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ], and 14/25 included studies that evaluated the incidence of endometrial cancer in BRCAm [ 11 , 12 , 13 , 14 , 15 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ].…”

Section: Resultsmentioning

confidence: 99%

“…A total of 1613 endometrial cancer patients from 11 studies were tested for BRCA1/2 pathological variants [ 8 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. Uterine serous carcinoma was diagnosed in 1129 patients.…”

Section: Resultsmentioning

confidence: 99%

Endometrial Cancer and BRCA Mutations: A Systematic Review

Gasparri

Bellaminutti

Farooqi

et al. 2022

JCM

View full text Add to dashboard Cite

This systematic review identifies, evaluates, and summarises the findings of all relevant individual studies on the prevalence of BRCA mutation (BRCAm) in endometrial cancer patients and the incidence of endometrial cancer in BRCAm women patients. Consequently, the benefits and limits of a prophylactic hysterectomy at the time of the risk-reducing salpingo-oophorectomy are analysed and discussed. A systematic literature search was performed in the databases of PubMed, Cochrane, and Web of Science until May 2022; 13 studies met the eligibility criteria. Overall, 1613 endometrial cancer patients from 11 cohorts were tested for BRCA1/2 mutation. BRCA1/2m were identified in 4.3% of women with endometrial cancer (70/1613). BRCA1m was the most represented (71.4%) pathogenic variant. Alongside, a total of 209 BRCAm carriers from 14 studies were diagnosed with endometrial cancer. Only 5 out of 14 studies found a correlation between BRCAm and an increased risk of endometrial cancer. Nevertheless, two studies found a statistical difference only for BRCA1m women. The present systematic review does not provide strong evidence in favour of performing routine hysterectomy at the time of risk-reducing salpingo-oophorectomy; however, it provides epidemiological data that can be useful for counselling patients in order to offer a tailored approach.

show abstract

“…However, a significant proportion of endometrial serous adenocarcinomas can show WT1 immunoreactivity with 44% of cases in one study exhibiting some degree of positivity 87. In contrast, HER2 overexpression appears more characteristic of endometrial serous adenocarcinoma although a wide range in the proportion of positive cases has been reported 88–91. Mutation-type p53 staining is almost universal in endometrial and tubo-ovarian high-grade serous adenocarcinomas but different expression patterns (e.g.…”

Section: Distinction Of Independent Primary Carcinomas Of the Endometmentioning

confidence: 91%

Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites

Stewart

Crum

McCluggage

et al. 2019

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

In most cases of suspected endometrial neoplasia tumor origin can be correctly assigned according to a combination of clinical, radiologic, and pathologic features, even when the latter are based upon the examination of relatively small biopsy samples. However there are well-recognized exceptions to this rule which continue to create diagnostic difficulty, and sometimes difficulties persist even after the detailed examination of resection specimens. Among the most common problems encountered in practice are the distinction of primary endometrial and primary endocervical adenocarcinomas, and the determination of tumor origin when there is synchronous, multifocal involvement of gynecologic tract sites, for example the endometrium and the ovary. However, accurate diagnosis in these cases is important because this has significant staging, management and prognostic implications. In this review we discuss the value and limitations of key morphologic, immunophenotypic and molecular findings in these diagnostic scenarios.

show abstract

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma

Cited by 15 publications

References 29 publications

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

Endometrial Cancer and BRCA Mutations: A Systematic Review

Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites

Contact Info

Product

Resources

About